InnoCare Pharma Collaborates with ArriVent Biopharma

InnoCare Pharma and ArriVent Biopharma have entered into a clinical development collaboration to assess the combination of two investigational drugs, ICP-189 and furmonertinib, for the treatment of advanced non-small cell lung cancer (NSCLC). Under the agreement, InnoCare and ArriVent will jointly conduct a clinical study to evaluate the efficacy and safety of combining ICP-189 with furmonertinib in patients with advanced NSCLC. ICP-189 is an oral allosteric inhibitor of SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase), a protein involved in cell signalling pathways. It is developed as a potential treatment for solid tumours, either as a standalone therapy or in combination with other anti-tumour agents. Early studies of ICP-189 have shown promising pharmacokinetics (PK), a long half-life, and favourable safety and tolerability. This collaboration represents an opportunity for ArriVent to expand its furmonertinib clinical development programme beyond monotherapy and explore the potential benefits of combination therapy in this setting. If the clinical trials are successful and the combination therapy is approved, the combination of furmonertinib with SHP2 inhibitors like ICP-189 will provide an additional treatment option for patients with advanced or metastatic lung cancer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!